Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study-Reference-Cited by-同舟云学术

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

Published:2016-12 Issue:10063 Volume:388 Page:3017-3026
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Finkel Richard S,Chiriboga Claudia A,Vajsar Jiri,Day John W,Montes Jacqueline,De Vivo Darryl C,Yamashita Mason,Rigo Frank,Hung Gene,Schneider Eugene,Norris Daniel A,Xia Shuting,Bennett C Frank,Bishop Kathie M

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA);Wirth;Hum Mutat,2000

2. Spinal muscular atrophy: diagnosis and management in a new therapeutic era;Arnold;Muscle Nerve,2015

3. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens;Sugarman;Eur J Hum Genet,2012

4. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications;Zerres;Arch Neurol,1995

5. Observational study of spinal muscular atrophy type I and implications for clinical trials;Finkel;Neurology,2014

Cited by 810 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy;Cellular and Molecular Life Sciences;2024-09-10

2. Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis;Neurology and Therapy;2024-09-02

3. Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment;Pediatric Neurology;2024-09

4. Evaluation of the Efficacy of Nusinersen Treatment in Patients with Late-onset SMA Using the Hammersmith Functional Motor Scale Expanded;Journal of Dr Behcet Uz Children s Hospital;2024-08-27

5. Therapeutic suppression ofTubb4arescues H-ABC leukodystrophy;2024-08-27